KRTL BioTech

Voss Capital backs a strategic review at Griffon, and a new opportunity to create value may emerge

Voss Capital backs a strategic review at Griffon, and a new opportunity to create value may emerge

The investor launched a proxy fight, won a board seat and now endorses a strategic review at Griffon. Here's what might be next.